These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

607 related items for PubMed ID: 23267717

  • 21. Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
    Pal SK, Signorovitch JE, Reichmann WM, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.
    Clin Genitourin Cancer; 2016 Apr; 14(2):160-7.e3. PubMed ID: 26707954
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L, Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A.
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
    Hutson TE.
    Oncologist; 2011 May; 16 Suppl 2(Suppl 2):14-22. PubMed ID: 21346036
    [Abstract] [Full Text] [Related]

  • 26. Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
    Vanhuyse M, Penel N, Caty A, Fumagalli I, Alt M, Zini L, Adenis A.
    Bull Cancer; 2012 Dec; 99(12):100-6. PubMed ID: 23220100
    [Abstract] [Full Text] [Related]

  • 27. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
    Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, Dreicer R, Bukowski RM, Rini BI.
    Cancer; 2010 Dec 01; 116(23):5383-90. PubMed ID: 20806321
    [Abstract] [Full Text] [Related]

  • 28. Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
    van der Zanden LFM, Vermeulen SH, Oskarsdottir A, Maurits JSF, Diekstra MHM, Ambert V, Cambon-Thomsen A, Castellano D, Fritsch A, Garcia Donas J, Guarch Troyas R, Guchelaar HJ, Hartmann A, Hulsbergen-van de Kaa C, Jaehde U, Junker K, Martinez-Cardus A, Masson G, Oosterwijk-Wakka J, Radu MT, Rafnar T, Rodriguez-Antona C, Roessler M, Ruijtenbeek R, Stefansson K, Warren A, Wessels L, Eisen T, Kiemeney LALM, Oosterwijk E.
    Urol Oncol; 2017 Aug 01; 35(8):529.e9-529.e16. PubMed ID: 28385611
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
    de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF.
    Ned Tijdschr Geneeskd; 2008 Feb 16; 152(7):371-5. PubMed ID: 18380383
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K, Bergmann L, Jäger E, Jakse G, Wirth M, Keilholz U, interdisziplinäre Arbeitsgruppe Nierenzellkarzinom der Deutschen Krebsgesellschaft e.V. (DKG).
    Aktuelle Urol; 2009 Jan 16; 40(1):27-30. PubMed ID: 19177318
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
    Soerensen AV, Donskov F, Kjellberg J, Ibsen R, Hermann GG, Jensen NV, Fode K, Geertsen PF.
    Eur Urol; 2015 Sep 16; 68(3):516-22. PubMed ID: 25533417
    [Abstract] [Full Text] [Related]

  • 36. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
    Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D.
    BMC Cancer; 2009 Jan 27; 9():34. PubMed ID: 19173737
    [Abstract] [Full Text] [Related]

  • 37. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V, Lin X, Kalanovic D, Simantov R.
    Eur Urol; 2016 Dec 27; 70(6):1006-1015. PubMed ID: 27238653
    [Abstract] [Full Text] [Related]

  • 38. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW, Chan AL.
    Clin Ther; 2011 Jun 27; 33(6):708-16. PubMed ID: 21704235
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
    Khambati HK, Choueiri TK, Kollmannsberger CK, North S, Bjarnason GA, Vaishampayan UN, Wood L, Knox JJ, Tan MH, MacKenzie MJ, Donskov F, Rini BI, Heng DY, International mRCC Database Consortium.
    Clin Genitourin Cancer; 2014 Oct 27; 12(5):354-8. PubMed ID: 24819320
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.